The American Journal of Medicine
Volume 120, Issue 4, Supplement 1 , Pages S3-S9 , April 2007

Heterogeneity of Treatment Effects: Implications for Guidelines, Payment, and Quality Assessment

  • Sheldon Greenfield, MD

      Affiliations

    • Center for Health Policy Research, Department of Medicine, University of California–Irvine School of Medicine, Irvine, California, USA
    • Corresponding Author InformationRequests for reprints should be addressed to: Sheldon Greenfield, MD, Center for Health Policy Research, Department of Medicine, University of California–Irvine School of Medicine, 111 Academy, Suite 220, Irvine, California 92697-5800.
    • ,
  • Richard Kravitz, MD, MSPH

      Affiliations

    • Center for Health Services Research in Primary Care, Lawrence J. Ellison Ambulatory Care Center, University of California–Davis, Sacramento, California, USA
    • ,
  • Naihua Duan, PhD

      Affiliations

    • Health Services Research Center, Semel Institute for Neuroscience and Human Behavior, University of California–Los Angeles, Los Angeles, California, USA
    • ,
  • Sherrie H. Kaplan, PhD, MPH

      Affiliations

    • Center for Health Policy Research, Department of Medicine, University of California–Irvine School of Medicine, Irvine, California, USA

References 

  1. Goldstein DB. Pharmacogenetics in the laboratory and the clinic. N Engl J Med. 2003;348:553–556
  2. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7:201–204
  3. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18
  4. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82:661–687
  5. Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717
  6. Terris S. Calcium plus vitamin D and the risk of fractures. N Engl J Med. 2006;354:2285–2287
  7. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354:795–808
  8. Ernst E. Glucosamine and chondroitin sulfate for knee osteoarthritis. N Engl J Med. 2006;354:2184–2185
  9. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669–683
  10. Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med. 2006;354:1744–1746
  11. Brindis RG, Spertus J. The role of academic medicine in improving health care quality. Acad Med. 2006;81:802–806
  12. Pronovost P, Holzmueller CG, Needham DM, et al. How will we know patients are safer? (An organization-wide approach to measuring and improving safety). Crit Care Med. 2006;34:1988–1995
  13. Chassin MR. Does paying for performance improve the quality of health care?. Med Care Res Rev. 2006;63:122S–125S
  14. Levenson S. “Pay for performance”: can it help improve long-term care?. J Am Med Dir Assoc. 2006;7:262–264
  15. Goldfield N, Burford R, Averill R, et al. Pay for performance: an excellent idea that simply needs implementation. Qual Manag Health Care. 2005;14:31–44
  16. Petersen LA, Woodard LD, Urech T, Daw C, Sookanan S. Does pay-for-performance improve the quality of health care?. Ann Intern Med. 2006;145:265–272
  17. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–724
  18. Tan KB. Clinical practice guidelines: a critical review. Int J Health Care Qual Assur Inc Leadersh Health Serv. 2006;19:195–220
  19. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess. 2004;8:iii–xi1
  20. Jamtvedt G, Young JM, Kristoffersen DT, O’Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2006;(2):CD000259
  21. Frolich A, Talavera JA, Broadhead P, Adams DR. A behavioral model of clinician responses to incentives to improve quality. Health Policy. 2007;80:179–193
  22. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626–631
  23. Litwin MS, Greenfield S, Elkin EP, et al. Assessment of prognosis with the Total Illness Burden Index for Prostate Cancer (TIBI-CaP): aiding clinicians in treatment choice. 2006;Presented at the annual meeting of the American Urological Association, May 20; Atlanta, Georgia.
  24. Greenfield S, Kaplan SH, Nicolucci A. The diabetes patient’s “other” diseases lead to 5-year mortality. 2006;Presented at the Midwest Society of General Internal Medicine, Quality Summit II. September 29; Chicago, Illinois.
  25. Longford NT. Selection bias and treatment heterogeneity in clinical trials. Stat Med. 1999;18:1467–1474
  26. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857–865
  27. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127:788–795
  28. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–2551
  29. Lip GY, Lowe GD. ABC of atrial fibrillation: antithrombotic treatment for atrial fibrillation. BMJ. 1996;312:45–49
  30. Hayward RA, Kent DM, Vijan S, Hofer TP. Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood). 2005;24:1571–1581
  31. Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst. 2005;97:412–413
  32. Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995;5:335–346
  33. McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med. 2003;9:424–430
  34. Huppert JD, Schultz LT, Foa EB, et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. Am J Psychiatry. 2004;161:1485–1487
  35. Senn S. Individual response to treatment: is it a valid assumption?. BMJ. 2004;329:966–968
  36. Materson BJ. Variability in response to antihypertensive drugs. Am J Med. 2007;120:S10–S20
  37. Carson CC. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol. 2005;96:37M–41M
  38. Lassila HC, Stoehr GP, Ganguli M, et al. Use of prescription medications in an elderly rural population: the MoVIES Project. Ann Pharmacother. 1996;30:589–595
  39. Stoehr GP, Ganguli M, Seaberg EC, Echement DA, Belle S. Over-the-counter medication use in an older rural community: the MoVIES Project. J Am Geriatr Soc. 1997;45:158–165
  40. Routledge PA, O’Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57:121–126
  41. Fortin M, Dionne J, Pinho G, et al. Randomized controlled trials: do they have external validity for patients with multiple comorbidities?. Ann Fam Med. 2006;4:104–108
  42. Rothwell PM, Warlow CP European Carotid Surgery Trialists’ Collaborative Group. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. Lancet. 1999;353:2105–2110
  43. Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?. Stroke. 2003;34:464–467
  44. Pocock SJ, McCormack V, Gueyffier F, et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323:75–81
  45. Slotman GJ. Prospectively validated prediction of organ failure and hypotension in patients with septic shock: the Systemic Mediator Associated Response Test (SMART). Shock. 2000;14:101–106
  46. Stier DM, Greenfield S, Lubeck DP, et al. Quantifying comorbidity in a disease-specific cohort: adaptation of the total illness burden index to prostate cancer. Urology. 1999;54:424–429
  47. Zimmerman JE, Wagner DP, Draper EA, et al. Evaluation of acute physiology and chronic health evaluation III predictions of hospital mortality in an independent database. Crit Care Med. 1998;26:1317–1326
  48. Selker HP, Griffith JL, Beshansky JR, et al. Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med. 1997;127:538–556
  49. Lagakos SW. The challenge of subgroup analyses—reporting without distorting. N Engl J Med. 2006;354:1667–1669
  50. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry. 2006;59:990–996
  51. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA. 2006;296:1286–1289
  52. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003;138:593–602

PII: S0002-9343(07)00135-0

doi: 10.1016/j.amjmed.2007.02.002

The American Journal of Medicine
Volume 120, Issue 4, Supplement 1 , Pages S3-S9 , April 2007

Article Tools

* Image Usage & Resolution